Fluorodeoxyglucose News and Research

RSS

FDG-PET safe and accurate in detecting dementia, Alzheimer's

In a new review of imaging studies spanning more than ten years, scientists find that a method of positron emission tomography (PET) safely and accurately detects dementia, including the most common and devastating form among the elderly, Alzheimer's disease.

7 Jan 2012

ACS to honor Brookhaven Lab's senior chemist for brain research

Joanna Fowler, a senior chemist and director of radiotracer chemistry, instrumentation, and biological imaging at the U.S. Department of Energy's Brookhaven National Laboratory, is one of 23 women from around the world who has been chosen to receive a Distinguished Women in Chemistry/Chemical Engineering Award, sponsored by the American Chemical Society (ACS).

27 Jun 2011

Combining CT with FDG-PET improves treatment options for head, neck cancer patients

Combining computerized tomography with fluorodeoxyglucose positron emission tomography images results in significantly more defined tumor outlines and potentially different treatment options in head and neck cancer patients compared to using CT alone, according to research presented today, at the Cancer Imaging and Radiation Therapy Symposium in Atlanta.

30 Apr 2011

New PET imaging clinical trial to improve early esophageal, lung cancer detection

Can a simple imaging test help predict the success of cancer treatment, even before the treatment is complete? To begin to answer this question, a new National Cancer Institute-funded clinical trial is using a novel PET imaging technique that could improve the early detection of tumor growth during treatment for esophageal and lung cancer.

29 Apr 2011

TOF positron emission tomography scans can improve cancer detection

For the first time, quantitative-not qualitative-data analysis has demonstrated that time-of-flight positron emission tomography scans can improve cancer detection.

2 Mar 2011

MedImmune announces MEDI-573 preclinical results against many solid tumors

MedImmune's Oncology group announced today preclinical results showing that MEDI-573, a targeted monoclonal antibody, broadly suppresses pathways that have been shown to play a critical role in the development and progression of many solid tumors.

21 Jan 2011

Eckert & Ziegler enters exclusive sales agreement with Zyklotron for Fluorodeoxyglucose

Eckert & Ziegler Strahlen- und Medizintechnik AG, a company specializing in special compounds for the diagnosis and treatment of cancer, via its subsidiary company Eckert & Ziegler f-con Deutschland GmbH closed an exclusive sales agreement with the Karlsruhe-based ZAG Zyklotron AG for the regular delivery of Fluorodeoxyglucose (18F) (FDG). FDG is used in the context of the so called Positron Emission Tomography (PET) for the safe and quick recognition of even the smallest tumour foci.

23 Nov 2010

FDG positron emission tomography allows early diagnosis of gall bladder cancer

Researchers at the University of Granada and the Department of Nuclear Medicine, Hospital Virgen de las Nieves at Granada found that the metabolic imaging diagnosis technique based on the analysis of a structural analog of glucose labeled with a positron-emitting compound (18F) allows early diagnosis of gall bladder cancer, a relatively rare disease with high mortality rates among most patients suffering from it.

15 Oct 2010

Study shows molecular imaging benefits treatment planning for wide spectrum of cancers

A series of studies published in the September Journal of Nuclear Medicine (JNM) show that molecular imaging plays a critical role in the evaluation and treatment planning for a broad spectrum of cancers, including thyroid cancer and lymphoma.

3 Sep 2010

Cell>Point completes cancer diagnostic phase 2 trial; reports favorable trends in primary tumor imaging

Cell>Point announced today that it has closed the Phase 2 portion of its Phase 2/3 trial of 99mTc-EC-G in evaluating patients with non-small cell lung cancer.

29 Jun 2010

MDS Nordion, Guerbet, Cyceron collaborate to develop new PET radiotracers for cancer diagnostics

MDS Nordion, a leading provider of products and services to the global health science market, Guerbet, a pharmaceutical group specialized in medical imaging, and Cyceron, a biomedical imaging centre in France, announced today they have entered into an agreement to develop new Positron Emission Tomography (PET) radiotracers for cancer diagnostics.

24 Jun 2010

TF2 bispecific antibody pretargeted therapy prolongs survival in animal model of human colonic cancer

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that pretargeted therapy with TF2, a bispecific antibody against carcinoembryonic antigen (CEA) and a small peptide, delayed tumor growth and prolonged survival in an animal model of human colonic cancer.

10 Jun 2010

Molecular imaging can help physicians identify aortic dissection: Research

According to research published in the May issue of The Journal of Nuclear Medicine, molecular imaging can help physicians identify aortic dissection-an often fatal blood vessel condition-and help guide treatment.

3 May 2010

Study shows imaging technique useful for planning cardiac procedures

For a patient with heart failure, checking whether the heart could benefit from bypass surgery or a stent is critical to ensuring survival. One imaging technique, positron emission tomography (PET) with the imaging agent fluorodeoxyglucose (FDG), may provide doctors with the information they need to make more informed treatment decisions, according to research published in the April issue of The Journal of Nuclear Medicine (JNM).

2 Apr 2010

CMS requested for coverage of two FDG PET scans during the initial treatment

Seven medical imaging groups wrote a joint letter to the Centers for Medicare and Medicaid Services (CMS) to formally request coverage of two fluorodeoxyglucose (FDG) positron emission tomography (PET) scans for a patient during the initial treatment evaluation. Currently, CMS covers only one FDG-PET study during initial treatment-a limitation that the groups believe is contrary to good clinical practice under certain circumstances.

20 Oct 2009

White House honors PET researcher with National Science Award

Joanna Fowler, Ph.D., a major contributor to brain research and a pioneer in molecular imaging, is being recognized by the White House with the National Medal of Science-the highest award for lifetime achievement in science. Eight other researchers will join Fowler to receive the award at a White House ceremony on October 7.

8 Oct 2009

New molecular imaging technique raises hope for common malignant female tumor

A promising new molecular imaging technique may provide physicians and patients with a noninvasive way to learn more information about a type of cancer of the uterus lining called "endometrial carcinoma"-one of the most common malignant female tumors. This research was presented in a study published in the October issue of The Journal of Nuclear Medicine.

1 Oct 2009

Fast track assessment facilities can contribute to timely evaluation of lung malignancies

Research published in the October 2009 issue of the Journal of Thoracic Oncology has found an effective combination of positron emission tomography (PET)/computed tomography (CT) (PET/CT) tests to diagnose lung cancer in a "fast-tracked" outpatient setting. This novel approach to the diagnosis of lung cancer demonstrated a high level of sensitivity (97%) and accuracy (82%).

1 Oct 2009

Senior chemist receives nation's highest award for achievement in science

Joanna Fowler, a senior chemist and Director of the Radiotracer Chemistry, Instrumentation and Biological Imaging Program at the U.S. Department of Energy's Brookhaven National Laboratory, will be awarded the National Medal of Science at a White House ceremony on October 7. She is one of nine researchers named by President Barack Obama to receive the nation's highest award for lifetime achievement in science.

25 Sep 2009

PET/CT may improve prognosis for patients with inflammatory breast cancer

In the largest study to date to evaluate fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG-PET/CT) in the initial staging of inflammatory breast cancer (IBC), researchers were able to identify the precise location and extent of metastasis (spread of disease), offering the potential for a better prognosis for patients with this rare, but aggressive form of breast cancer.

2 Feb 2009